Department of Biochemistry, School of Basic Medical Sciences, Wenzhou Medical University.
Department of Orthopedics, Wenzhou Medical University First Affiliated Hospital.
Rheumatology (Oxford). 2021 Dec 1;60(12):5833-5842. doi: 10.1093/rheumatology/keab133.
In this study, we explored the effect of semaphorin5A (SEMA5A) on RA pathogenesis and its specific TSP1 domain on pannus formation.
The expression of SEMA5A was detected in the synovium, the fibroblast-like synoviocytes (FLSs) and the SF of RA patients and healthy controls (HCs) by real-time quantitative PCR (q-PCR), immunohistochemistry staining, western blot and ELISA. SEMA5A-mAb intervention was performed to appraise the severity of joints in the CIA model. Transcriptome sequencing and bioinformatics analysis in SEMA5A-transfected FLSs from HCs were performed to screen differentially expressed genes after SEMA5A overexpression. An MTT assay in RA-FLSs, a chicken embryo allantoic membrane experiment and a tube formation experiment were used to clarify the influence of SEMA5A on cell proliferation and angiogenesis. Furthermore, a rescue experiment verified the function of the TSP1 domain of SEMA5A in the progress of RA with Sema5a-/- CIA mice.
The expression of SEMA5A increased in RA compared with that in HCs. Simultaneously, SEMA5A-mAbs significantly attenuated joint injury and the inflammatory response in CIA models. In addition, transcriptome sequencing and angiogenesis-related experiments verified the ability of SEMA5A to promote FLS proliferation and angiogenesis. Moreover, TSP1 was proved to be an essential domain in SEMA5A-induced angiogenesis in vitro. Additionally, rescue of TSP1-deleted SEMA5A failed to reduce the severity of arthritis in a CIA model constructed with Sema5a -/- mice.
In summary, upregulation of SEMA5A was first confirmed in pathological lesions of RA patients. Furthermore, treatment with SEMA5A-mAbs attenuated the progress of RA in the CIA model. Moreover, TSP1 was indicated as the key domain of SEMA5A in the promotion of pannus formation in RA.
本研究旨在探讨 SEMA5A 对 RA 发病机制的影响及其特定的 TSP1 结构域在血管翳形成中的作用。
采用实时定量 PCR(q-PCR)、免疫组织化学染色、western blot 和 ELISA 检测 RA 患者和健康对照者(HCs)滑膜、成纤维样滑膜细胞(FLSs)和滑膜液中 SEMA5A 的表达。采用 SEMA5A-mAb 干预 CIA 模型,评估关节严重程度。对来自 HCs 的 SEMA5A 转染的 FLSs 进行转录组测序和生物信息学分析,筛选 SEMA5A 过表达后差异表达的基因。采用 MTT 检测 RA-FLSs 的细胞增殖、鸡胚尿囊膜实验和管形成实验检测 SEMA5A 对细胞增殖和血管生成的影响。此外,通过 Sema5a-/- CIA 小鼠的拯救实验验证 SEMA5A 的 TSP1 结构域在 RA 进展中的作用。
与 HCs 相比,RA 中 SEMA5A 的表达增加。同时,SEMA5A-mAbs 可显著减轻 CIA 模型中的关节损伤和炎症反应。此外,转录组测序和血管生成相关实验验证了 SEMA5A 促进 FLS 增殖和血管生成的能力。此外,TSP1 被证明是 SEMA5A 诱导体外血管生成的必需结构域。此外,在 Sema5a -/- 小鼠构建的 CIA 模型中,TSP1 缺失的 SEMA5A 的挽救未能减轻关节炎的严重程度。
总之,本研究首次证实 SEMA5A 在 RA 患者的病理损伤中上调。此外,SEMA5A-mAb 治疗可减轻 CIA 模型中 RA 的进展。此外,TSP1 被确定为 SEMA5A 促进 RA 血管翳形成的关键结构域。